Edition:
United States

Sumitomo Dainippon Pharma Co Ltd (4506.T)

4506.T on Tokyo Stock Exchange

2,338JPY
22 Jun 2018
Change (% chg)

¥51 (+2.23%)
Prev Close
¥2,287
Open
¥2,289
Day's High
¥2,350
Day's Low
¥2,287
Volume
1,608,000
Avg. Vol
1,572,233
52-wk High
¥2,414
52-wk Low
¥1,397

Latest Key Developments (Source: Significant Developments)

Carna Biosciences and Sumitomo Dainippon Pharma sign agreement on joint research, development, and commercialization of kinase inhibitors
Tuesday, 27 Mar 2018 03:47am EDT 

March 27 (Reuters) - Carna Biosciences Inc <4572.T>:Says it and Sumitomo Dainippon Pharma Co Ltd <<<4506.T>>> , signed an agreement on joint research with the aim of discovering novel kinase inhibitors for psychiatric and neurological disorders, as well as on the subsequent development and commercialization of such therapeutic agent.  Full Article

Poxel And Sumitomo Dainippon Pharma Announce Initiation Of Phase 3 Program For Imeglimin In Japan
Wednesday, 27 Dec 2017 02:00am EST 

Dec 27 (Reuters) - POXEL SA ::POXEL AND SUMITOMO DAINIPPON PHARMA <<<4506.T>>> ANNOUNCE INITIATION OF PHASE 3 PROGRAM FOR IMEGLIMIN, AN INVESTIGATIONAL THERAPEUTIC AGENT FOR TYPE 2 DIABETES, IN JAPAN.JAPANESE NEW DRUG APPLICATION SUBMISSION FOR IMEGLIMIN TARGETED IN 2020.  Full Article

Sumitomo Dainippon Pharma says result of early-retirement program
Sunday, 24 Dec 2017 09:25pm EST 

Dec 25 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T> ::Says 86 employees took up the offer of the early-retirement program announced on Sept. 27.Effective date of retirement is March 31, 2018.A premium will be added to the normal retirement allowance of eligible applicants.Says eligible applicants will also have the option to receive job-placement assistance.  Full Article

Sunovion Receives FDA Approval for Lonhala Magnair Inhalation Solution to Treat COPD
Tuesday, 5 Dec 2017 08:48pm EST 

Dec 5 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>::SUNOVION RECEIVES FDA APPROVAL FOR LONHALA MAGNAIR INHALATION SOLUTION TO TREAT COPD.SUNOVION EXPECTS LONHALA MAGNAIR TO BE AVAILABLE IN U.S. PHARMACIES IN EARLY 2018.SUNOVION RECEIVES FDA APPROVAL FOR LONHALA MAGNAIR INHALATION SOLUTION TO TREAT COPD.  Full Article

Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda (Lurasidone Hydrochloride) in Europe
Tuesday, 21 Nov 2017 02:32am EST 

Nov 21 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it and Angelini S.p.A announced today that the companies have formed a partnership with the goal to expand availability in Europe of Latuda®, an atypical antipsychotic which was created by the co .Under the terms of the agreement, Sunovion Pharmaceuticals Europe Ltd., a subsidiary company of Sumitomo Dainippon Pharma Group, has granted Angelini exclusive commercialization rights for LATUDA in 29 European countries and in Turkey.  Full Article

Sumitomo Dainippon Pharma and Poxel announce strategic partnership for development and commercialization of Imeglimin
Monday, 30 Oct 2017 03:06am EDT 

Oct 30 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it signed an agreement with Poxel SA on Oct. 30, for the development and commercialization of Imeglimin, an investigational therapeutic agent for type 2 diabetes, in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries.Under the Agreement, Poxel SA is entitled to receive an upfront payment of approximately 4.75 billion yen and future potential development milestone payments of up to 2.75 billion yen .  Full Article

Poxel and Sumitomo Dainippon Pharma in partnership to develop and sell Imeglimin in Asia
Monday, 30 Oct 2017 02:30am EDT 

Oct 30 (Reuters) - POXEL SA ::SUMITOMO DAINIPPON PHARMA AND POXEL ANNOUNCE STRATEGIC PARTNERSHIP FOR DEVELOPMENT AND COMMERCIALIZATION OF IMEGLIMIN, AN INVESTIGATIONAL THERAPEUTIC AGENT FOR TYPE 2 DIABETES, IN JAPAN, CHINA AND ELEVEN OTHER ASIAN COUNTRIES.‍POXEL AND SUMITOMO DAINIPPON PHARMA TO JOINTLY DEVELOP IMEGLIMIN FOR TREATMENT OF TYPE 2 DIABETES IN JAPAN,​.‍SUMITOMO DAINIPPON PHARMA ASSUMES PHASE 3 AND COMMERCIALIZATION COSTS​.‍POXEL RECEIVES AN UPFRONT PAYMENT OF ¥4.75 BILLION (APPROXIMATELY EUR 36 MILLION, $42 MILLION)​.‍SUMITOMO DAINIPPON PHARMA SOLELY RESPONSIBLE FOR IMEGLIMIN IN CHINA, SOUTH KOREA, TAIWAN AND 9 OTHER SOUTHEAST ASIAN COUNTRIES​.‍PHASE 3 PROGRAM FOR IMEGLIMIN IN JAPAN ON TRACK TO BE INITIATED IN Q4 OF CY 2017​.‍RECEIVES FUTURE POTENTIAL DEVELOPMENT MILESTONE PAYMENTS AND SALES-BASED PAYMENTS OF UP TO ¥29.25 BILLION​.  Full Article

Kitasato Institute and Sumitomo Dainippon Pharma signs joint drug discovery research agreement
Tuesday, 24 Oct 2017 04:22am EDT 

Oct 24 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it and the Kitasato Institute have signed a joint drug discovery research agreement for infections caused by bacteria with antimicrobial resistance (AMR).  Full Article

Sumitomo Dainippon Pharma unit receives Complete Response Letter from FDA for SUN-101/eFlow® New Drug Application for chronic obstructive pulmonary disease
Sunday, 28 May 2017 10:49pm EDT 

May 29(Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says its US-based unit Sunovion Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for SUN-101/eFlow®(glycopyrrolate) for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD),including chronic bronchitis and/or emphysema, on May 26 (US Eastern time).Says the CRL does not require unit to conduct any additional clinical studies for the approval of SUN-101/eFlow®.  Full Article

Sumitomo Dainippon Pharma unit to buy 100 pct stake in Cynapsus Therapeutics Inc. at $624 mln
Monday, 3 Oct 2016 11:40pm EDT 

Sumitomo Dainippon Pharma <4506.T>:Says its subsidiary will buy 100 percent stake in Cynapsus Therapeutics Inc. at $624 million by the end of Dec..  Full Article

BRIEF-Sumitomo Dainippon Pharma and JCR Pharmaceuticals sign license agreement

* Says it and JCR Pharmaceuticals Co Ltd signed a license agreement on Blood-Brain Barrier Penetration Technology for creation of a therapeutic agent for Central Nervous System Diseases